Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases

Abstract

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

1 . A pharmaceutical composition formulated as a suspension for oral administration, the suspension comprising solid particles of an asprin in an oil carrier,
 the asprin solid particles in an amount of at least 20% by weight of the pharmaceutical composition,   the oil carrier in an amount of at least 10% by weight of the pharmaceutical composition, and   the oil carrier comprising (i) at least 80% of one or more free fatty acids, each of the one or more free fatty acids having at least 8 carbon atoms and being a liquid at room temperature and (ii) a phospholipid.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the asprin solid particles are in an amount of about 25% to about 50% by weight of the pharmaceutical composition. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the oil carrier is in an amount of at least 40% by weight of the pharmaceutical composition. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the oil carrier is in an amount of at least 45% by weight of the pharmaceutical composition. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the oil carrier is in an amount of at least 50% by weight of the pharmaceutical composition. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the one or more free fatty acids are in an amount of at least 85% by weight of the pharmaceutical composition. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the one or more free fatty acids are in an amount of at least 90% by weight of the pharmaceutical composition. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the one or more free fatty acids are in an amount of at least 95% by weight of the pharmaceutical composition. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the one or more free fatty acids includes a saturated free fatty acid, an unsaturated free fatty acid, or both saturated and unsaturated free fatty acids. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the oil carrier comprises one free fatty acid having at least 8 carbon atoms. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the one free fatty acid is an oleic acid. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the oil carrier comprises a plurality of different free fatty acids, each of the plurality of different free fatty acids having at least 8 carbon atoms. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the plurality of different free fatty acids includes a palmitic acid, a stearic acid, an oleic acid, a linoleic acid, a linolenic acid, or any combination thereof. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the free fatty acid is a lauric acid, a tridecylic acid, a myristic acid, a myristoleic acid, a pentadecyclic acid, a palmitic acid, a palmitoleic acid, a sapienic acid, a margaric acid, a stearic acid, an oleic acid, an elaidic acid, a vaccenic acid, a linoleic acid, a linoelaidic acid, an α-Linolenic acid, a γ-Linolenic acid, a stearidonic acid, a nonadecylic acid, an arachidic acid, an eicosenoic acid, a dihomo-γ-linolenic acid, a mead acid, an arachidonic acid, an eicosapentaenoic acid, a heneicosylic acid, a behenic acid, an erucic acid, a docosahexaenoic acid, a tricosylic acid, a lignoceric acid, a nervonic acid, or any combination thereof. 
     
     
         15 . The pharmaceutical composition of  claim 1 , wherein the phospholipid is a zwitterionic phospholipid. 
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein the phospholipid includes a phosphodiacylglyceride or a phosphosphingolipid. 
     
     
         17 . The pharmaceutical composition of  claim 1 , wherein the phospholipid is a phosphatidylcholine, a phosphatidylserine, a phosphatidylethanolamine, a phosphatidylinositol, a sphingomyelin, or any combination thereof. 
     
     
         18 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated in the absence of a solvent. 
     
     
         19 . A pharmaceutical composition formulated as a suspension for oral administration, the suspension comprising solid particles of an asprin in an oil carrier,
 the oil carrier being in an amount of at least 40% by weight of the pharmaceutical composition, and   the oil carrier comprising (i) at least 90% of one or more free fatty acids, each of the one or more free fatty acids having at least 8 carbon atoms and being a liquid at room temperature and (ii) a phospholipid.   
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the phospholipid is a zwitterionic phospholipid.